Financial Performance - Revenue for the third quarter was RMB 485,799,506.29, a decrease of 15.51% compared to the same period last year[4] - Net profit attributable to shareholders was RMB 99,435,565.54, down 58.04% year-on-year[4] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 84,926,745.33, a decline of 63.74% compared to the previous year[4] - The net cash flow from operating activities was RMB 192,325,709.34, a decrease of 57.11% year-on-year[4] - Basic earnings per share were RMB 0.13, down 59.38% compared to the same period last year[4] - Net profit attributable to shareholders decreased by 121.46% year-to-date due to intensified competition, declining sales revenue, and a decrease in the fair value of biological assets[11] - Net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 136.47% year-to-date, primarily due to similar factors as above[11] - Cash flow from operating activities decreased by 57.11% year-to-date, mainly due to reduced sales collections while employee compensation remained stable compared to the previous year[11] - Basic earnings per share decreased by 120.45% year-to-date, reflecting the impact of increased competition and declining sales revenue and gross margin[11] - Diluted earnings per share decreased by 120.45% year-to-date, consistent with the basic earnings per share decline[11] - Net profit attributable to shareholders for the current reporting period decreased by 58.04% due to intensified competition and declining sales revenue[11] - Net profit attributable to shareholders after deducting non-recurring gains and losses for the current reporting period decreased by 63.74%[11] - Basic earnings per share for the current reporting period decreased by 59.38% due to similar competitive pressures[11] - Diluted earnings per share for the current reporting period decreased by 59.38%, reflecting the same trends[11] Assets and Liabilities - Total assets at the end of the reporting period were RMB 9,525,184,807.98, a decrease of 5.01% from the end of the previous year[4] - Equity attributable to shareholders was RMB 8,002,435,682.20, down 3.34% compared to the end of the previous year[4] - As of September 30, 2024, the company's total current assets amounted to RMB 5.33 billion, a decrease from RMB 7.12 billion on December 31, 2023[18] - The total non-current assets as of September 30, 2024, were CNY 4,191,072,779.02, significantly higher than CNY 2,905,192,290.36 as of December 31, 2023, marking an increase of about 44.2%[21] - Total liabilities as of September 30, 2024, were CNY 1,534,350,209.75, down from CNY 1,746,119,215.39 at the end of 2023, a decrease of approximately 12.1%[20] - The total assets as of September 30, 2024, were CNY 9,525,184,807.98, compared to CNY 10,027,159,630.47 at the end of 2023, indicating a decline of about 5.0%[21] - The total equity attributable to shareholders as of September 30, 2024, was CNY 8,002,435,682.20, down from CNY 8,279,315,724.35 at the end of 2023, a decrease of about 3.4%[21] Cash Flow and Investments - The company's cash and cash equivalents decreased from RMB 2.86 billion at the end of 2023 to RMB 1.84 billion as of September 30, 2024[18] - The company's trading financial assets increased significantly from RMB 373.35 million to RMB 1.38 billion during the same period[18] - The company reported a net interest income of CNY 82,526,990.66 for the first three quarters of 2024, compared to CNY 108,316,598.07 in the same period of 2023, reflecting a decrease of approximately 23.9%[22] - Cash inflow from operating activities for the first three quarters of 2024 is 1,367,691,390.73, down from 1,874,131,001.01 in 2023, showing a decrease in cash generation[27] - The cash inflow from investment activities totaled 2,508,098,115.21, significantly increasing from 528,639,464.14 in the first three quarters of 2023[28] - The net cash flow from investment activities was -950,050,766.71, worsening from -137,147,755.87 in the same period of 2023[28] - The cash outflow from financing activities was 248,828,091.97, down from 333,289,197.75 in the first three quarters of 2023[29] - The net increase in cash and cash equivalents was -1,013,522,516.10, compared to -8,194,783.60 in the same period of 2023[29] - The ending balance of cash and cash equivalents was 1,840,124,511.87, a decrease from 2,891,274,796.93 at the end of the same period in 2023[29] - The cash inflow from recovering investments was 2,307,885,508.22, a substantial increase from 501,496,756.80 in the first three quarters of 2023[28] - The cash outflow for purchasing fixed assets and intangible assets was 188,019,727.66, up from 149,651,195.84 in the same period of 2023[28] - The cash paid for long-term assets was 3,270,129,154.26, significantly higher than 426,076,500.00 in the first three quarters of 2023[28] Operational Performance - The company signed new contracts worth approximately RMB 1.4 billion in the first three quarters, with a total order backlog of about RMB 2.65 billion as of the end of the reporting period[16] - The company reported a foreign exchange loss of -190,401,449.68 in the first three quarters of 2024, compared to -108,513,934.09 in 2023, indicating increased volatility in currency exchange[23] - The company experienced a credit impairment loss of -11,477,062.92 in the first three quarters of 2024, compared to -3,187,147.18 in 2023, reflecting worsening credit conditions[23] - The operating profit for the first three quarters of 2024 is -69,661,013.72, down from 392,084,940.00 in 2023, indicating a substantial decrease in operational performance[23] - The total comprehensive income for the first three quarters of 2024 is -79,103,195.69, a stark contrast to 336,381,200.67 in the previous year[25] - Basic and diluted earnings per share for the first three quarters of 2024 are both reported at -0.09, compared to 0.44 in 2023, indicating a loss per share[25] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period was 72,246, with the top ten shareholders holding significant stakes[12] - There were no changes in the top 10 shareholders due to securities lending or borrowing activities[15] Strategic Outlook - The company has not disclosed any new product or technology developments in the recent reporting period[16] - The company has not indicated any market expansion or acquisition strategies in the latest report[16] - The company has advised investors to be cautious due to various factors affecting order execution[16]
昭衍新药(06127) - 2024 Q3 - 季度业绩